PM360

APRIL 22, 2024

In this context, we shouldn’t just think of the Sacklers and Shkrelis and Holmeses of the world, who coupled regulatory noncompliance with lamentable ethical failures. With healthcare professionals becoming less accessible to biopharma reps, the emphasis has shifted toward patient empowerment.

Patients 52

Patients Biopharma Ethics Marketing 52

PM360

JUNE 24, 2024

This fuels an enormous need for effective patient communication and education as new therapies move through the biopharma pipeline. Those of us in the biopharma industry know how fraught drug development can be. As the saying goes, they are individually rare but collectively common. Many people, cumulatively, are affected.

Marketing 52

Marketing Patients Food and Drug Administration Education 52

Clarivate

JUNE 21, 2024

Similarly, the United States is considering frameworks that emphasize AI ethics, aiming to prevent bias and ensure AI systems are transparent and understandable (Intel.gov). However, we are also deliberately adopting a cautious approach (Cochrane, 2024).” References Cochrane, 2024. Available: [link] [Accessed 17/06/2024].

Training 81

Training Government Medical science Ethics 81

PM360

SEPTEMBER 30, 2024

In late 2023, Deloitte found that over half of 105 surveyed global biopharma leaders were committed to reducing environmental impact and advancing sustainability by minimizing water use, sourcing sustainable materials, and overhauling supply chains.

Manufacturing 52

Manufacturing Pharma Pharmaceutical Competition 52

PM360

JUNE 24, 2024

Yet from a risk-mitigation perspective, we anticipate a cautious, measured approach by most biopharma companies. A Bonus for Authenticity As biopharma professionals begin to routinely implement AI solutions, one thing we should all watch out for is how unique our work outputs are really going to be.

Healthcare 52

Healthcare Healthcare Patients Side effects 52

Clarivate

OCTOBER 7, 2024

Then, of course, there are the ethical considerations. Online] Available at: [link] [Accessed 1 10 2024]. For example, one study demonstrated 89% accuracy of in silico drug trials in populations of human cardiomyocyte models in predicting clinical arrhythmia — versus a 75% accuracy using animal models (Passini, 2017). Barrile, R.,

Food and Drug Administration 52

Food and Drug Administration Pharmacology Food Engineering 52